Author:
Cento V.,Barbaliscia S.,Lenci I.,Ruggiero T.,Magni C.F.,Paolucci S.,Babudieri S.,Siciliano M.,Pasquazzi C.,Ciancio A.,Perno C.F.,Ceccherini-Silberstein F.,Micheli V.,Troshina Y.,Biliotti E.,Milana M.,Melis M.,Teti E.,Lambiase L.,Menzaghi B.,Nicolini L.A.,Marenco S.,Di Maio V.C.,Aragri M.,Pecchioli A.,Bertoli A.,Sarrecchia C.,Macera M.,Coppola N.,Puoti M.,Romagnoli D.,Pellicelli A.,Bonora S.,Novati S.,Baldanti F.,Ghisetti V.,Andreoni M.,Taliani G.,Rizzardini G.,Angelico M.
Funder
Gilead Sciences
Bristol-Myers Squibb
Abbvie
Roche Diagnostics
Merck Sharp & Dohme
Janssen-Cilag
Abbott Molecular
ViiV Healthcare
Italian Ministry of Instruction
University and Research (MIUR)
Aviralia Foundation
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference14 articles.
1. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. September 2016 [cited 2016 10/04/2016].
2. EASL. Recommendations on Treatment of Hepatitis C 2016, update of September 2016 September 2016 [cited 2016 07/10/2016]. Available from: http://www.easl.eu/medias/cpg/HCV2016/English-report.pdf.
3. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice;Sarrazin;J Hepatol,2016
4. Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/− simeprevir in the TRIO network; Academic and community treatment of a real-world, heterogeneous population;Dieterich;Gastroenterology,2015